Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres II. In vitro investigation
N. Puri et Pj. Sinko, Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres II. In vitro investigation, J CONTR REL, 69(1), 2000, pp. 69-80
In the present study, sustaining the release of adjuvants was investigated
using microspheres as a means to increase the immune response (i.e. efficac
y) and, ultimately, to reduce adverse effects to vaccine components. To dat
e, most attempts have focused on sustaining the release of antigens. The ut
ility of currently used vaccine adjuvants may be improved by sustaining the
ir release. The development, modification and characterization of a two-com
ponent microsphere vaccine delivery system was demonstrated in our previous
report [Puri et al., J. Control. Release (2000) in press]. Briefly, ovalbu
min (OVA) was utilized as the model antigen (Ag) and delivery matrix and MD
P or threonyl-MDP served as the model adjuvants. The release pattern of MDP
was modulated from a physicochemically modified matrix of OVA microspheres
(OVA-MSs). The purpose of the present study was to evaluate the adjuvancy
of MDP in mice by modulating its release from OVA-MSs. Mice were immunized
intradermally (i.d.) with various preparations of OVA-MSs, using a single-s
hot-immunization technique. Positive and negative control preparations were
evaluated as well. An inverse relationship was observed between the in vit
ro release rate of MDP and the in vivo OVA-specific IgG antibody (Ab) immun
e response in mice. These results demonstrated that modulating the release
pattern of MDP or threonyl-MDP enhanced their adjuvant effect. In conclusio
n, the current results demonstrate that the sustained and controlled releas
e of adjuvants is extremely important for inducing a high level and prolong
ed period of immunostimulation while potentially minimizing therapy-limitin
g adverse effects. (C) 2000 Elsevier Science B.V. All rights reserved.